Bill

Bill > S689


MA S689

MA S689
Relative to patient access to biomarker testing to provide appropriate therapy


summary

Introduced
02/16/2023
In Committee
05/30/2024
Crossed Over
Passed
Dead
12/31/2024

Introduced Session

193rd General Court

Bill Summary

For legislation relative to patient access to biomarker testing to provide appropriate therapy. Financial Services.

AI Summary

This bill requires health insurance plans in Massachusetts, including those for state employees, Medicaid, and commercial plans, to cover biomarker testing for the purposes of diagnosis, treatment, management, or monitoring of a patient's disease or condition. Biomarker testing is defined as the analysis of a patient's tissue, blood, or other biospecimen to detect indicators of normal or pathogenic processes, or responses to a specific treatment. Coverage must be provided when the test is supported by medical evidence, such as FDA approvals, Medicare coverage determinations, or nationally recognized clinical guidelines. The bill also sets time limits for insurers to respond to prior authorization requests and provides a process for patients and providers to request exceptions to coverage policies.

Committee Categories

Business and Industry, Health and Social Services

Sponsors (30)

Last Action

Accompanied H1074 (on 06/20/2024)

Bill Topics

Banking, Finance, and Domestic Commerce
  • ‐ Insurance Regulation
Health
  • ‐ Health Insurance Reform

bill text


bill summary

Loading...

bill summary

Loading...

bill summary

Document Type Source Location Created
State Bill Page https://malegislature.gov/Bills/193/S689 03/11/2023
BillText https://malegislature.gov/Bills/193/S689.pdf 03/11/2023
Loading...